Literature DB >> 123758

Amino acid sequence studies on plasmin-derived fragments of human fibrinogen: amino-terminal sequences of intermediate and terminal fragments.

T Takagi, R F Doolittle.   

Abstract

The progressive changes in amino-terminal sequence brought about by the digestion of human fibrinogen by plasmin have been studied. In addition, the limit products (fragments D and E) have been isolated and characterized in the same way. These studies have confirmed the generally accepted scheme of fibrinogen being changed into a large molecular weight fragment X, which in turn is converted into an intermediate fragment Y and a limit fragment D, followed by the breakdown of fragment Y into an additional fragment D and another core fragment E. Our data allow the precise identification of several of the junctions being attacked, including one in a region of the gamma-chain whose sequence has not previously been reported. The cleavages are not singular in any case, however, and, as suggested by others, intermediate species exist which correspond to "early D," "late D," etc. In addition to localizing the exact bonds split by plasmin, we have been able to sequentially position the core fragments relative to each other, since the gamma-chain amino terminus of fragment D has been found to be contiguous to the known carboxy-terminal sequence of fragment E.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 123758     DOI: 10.1021/bi00676a010

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  16 in total

1.  Generation of forms of fragment E with differing thrombin-binding properties during digestion of fibrinogen by plasmin.

Authors:  C A Goodwin; V V Kakkar; M F Scully
Journal:  Biochem J       Date:  1992-02-01       Impact factor: 3.857

Review 2.  Natural anticoagulant mechanisms.

Authors:  R D Rosenberg; J S Rosenberg
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

3.  Fibrin-mediated vascular injury. Identification of fibrin peptides that mediate endothelial cell retraction.

Authors:  F N Rowland; M J Donovan; P T Picciano; G D Wilner; D L Kreutzer
Journal:  Am J Pathol       Date:  1984-12       Impact factor: 4.307

4.  Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure.

Authors:  C W Francis; V J Marder; G H Barlow
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

5.  Engineering kunitz domain 1 (KD1) of human tissue factor pathway inhibitor-2 to selectively inhibit fibrinolysis: properties of KD1-L17R variant.

Authors:  Madhu S Bajaj; Godwin I Ogueli; Yogesh Kumar; Kanagasabai Vadivel; Gregory Lawson; Sreejesh Shanker; Amy E Schmidt; S Paul Bajaj
Journal:  J Biol Chem       Date:  2010-11-29       Impact factor: 5.157

Review 6.  [Antibody mediated thrombolysis. A new therapeutic principle].

Authors:  C Bode; W Kübler
Journal:  Klin Wochenschr       Date:  1989-07-03

7.  Quantitative N-terminal analysis of fibrinogen-fibrin-related antigen [FR antigen] from human plasma.

Authors:  J U Harris; A J Johnson; C Merskey; M T Wang; D Robinson
Journal:  Biochem J       Date:  1979-12-01       Impact factor: 3.857

8.  gamma and alpha chains of human fibrinogen possess sites reactive with human platelet receptors.

Authors:  J Hawiger; S Timmons; M Kloczewiak; D D Strong; R F Doolittle
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

9.  Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.

Authors:  J H Wu; S L Diamond
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

10.  Synthetic peptide derivatives that bind to fibrinogen and prevent the polymerization of fibrin monomers.

Authors:  A P Laudano; R F Doolittle
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.